<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01141998</url>
  </required_header>
  <id_info>
    <org_study_id>Bang-01</org_study_id>
    <nct_id>NCT01141998</nct_id>
  </id_info>
  <brief_title>Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption</brief_title>
  <official_title>Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:

      The overall objective of this study is to learn more about the disease chronic pancreatitis
      and thus contribute to better treatments. The investigators will gain this by studying the
      effects of vitamin D in the body immune system and bones. The investigators will also study
      the uptake of vitamin D through the intestine compared with the amount of vitamin D obtained
      through exposure to UVB rays.

      The investigators have set a series of questions which the investigators want to answer with
      this experiment:

      Do patients with chronic pancreatitis have reduced absorption of vitamin D from the gut?

        -  Have the two treatment methods with vitamin D, UV radiation and tablets, the same
           success rate?

        -  Does the distribution of the white blood cells change when the vitamin D level increases
           and does it depend on whether the patient have UVB radiation or tablet with vitamin D?

        -  Will patients require reduced amounts of painkillers when vitamin D level increases?

        -  Does vitamin D have influence on blood sugar and thus the risk of diabetes or worsening
           of this?

        -  Could vitamin D affect the blood content of inflammation markers?

        -  Does the patient feel better when he takes vitamin D?

        -  Does bone strength increase when the patients receive grants of vitamin D?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>25-hydroxyvitamin D</measure>
    <time_frame>Week 0, 2, 6, 10, 14, 20, 30, 40, 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>T-lymphocytes subsets.</measure>
    <time_frame>Week 0, 10</time_frame>
    <description>Subsets of T-lymphocytes including regulatory T-lymphocytes (Tregs) and CD4+ and CD8+ lymphocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ionized calcium</measure>
    <time_frame>week 0, 2, 6, 10, 14, 20, 30, 40, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parathyroid hormone</measure>
    <time_frame>Week 0, 2, 6, 10, 14, 20, 30, 40, 52</time_frame>
    <description>To evaluate bone-metabolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL score</measure>
    <time_frame>Week 0, 10</time_frame>
    <description>Evaluation of self-reported health using two questionnaires:
QLQ-C30 QLQ-Pan(30)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <condition>Malabsorption Syndromes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D administered orally</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D administered via UVB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium, Dietary</intervention_name>
    <description>400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vitamin D administered orally</arm_group_label>
    <arm_group_label>Vitamin D administered via UVB</arm_group_label>
    <other_name>Unikalk Basic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>38 micrograms daily. Week 0-10.</description>
    <arm_group_label>Vitamin D administered orally</arm_group_label>
    <other_name>Unikalk Forte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>UVB</intervention_name>
    <description>Ultraviolet radiation type B administered in a tanning bed. One time weekly.</description>
    <arm_group_label>Vitamin D administered via UVB</arm_group_label>
    <other_name>Ergoline Flair 200</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>UV-filtered light.</intervention_name>
    <description>Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vitamin D administered orally</arm_group_label>
    <other_name>Ergoline Flair 200</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>38 micrograms daily. From week 14 to 52.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vitamin D administered orally</arm_group_label>
    <arm_group_label>Vitamin D administered via UVB</arm_group_label>
    <other_name>Unikalk Forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic pancreatitis

          -  Malabsorption

          -  Age min. 18 y.

          -  25-hydroxyvitamin D less than 75 nmol/l

          -  Body mass index &lt; 30

          -  Consent

        Exclusion Criteria:

          -  Acute pancreatitis

          -  Cirrhosis

          -  Ionized calcium &gt; 1.35 mmol/l

          -  Heart disease

          -  Former resection of gastro-intestinal tract.

          -  Pregnancy

          -  Pancreatic malignant disease

          -  History of skin cancer

          -  Other than skin cancer less then 5 y prior to inclusion in study

          -  Chronic kidney disease

          -  Type I diabetes

          -  Hemoglobin &lt; 5.0 mmol/l

          -  Participating in other studies

          -  Not suitable for inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens-Erik B Jensen, Ph.d.</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of osteoporosis, Hvidovre Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <last_update_submitted>December 22, 2011</last_update_submitted>
  <last_update_submitted_qc>December 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Ulrich Bang</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
    <mesh_term>Malabsorption Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

